675 articles in this topic
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
A comprehensive review reveals how the senescence secretome suppresses tumors early but drives progression, resistance, and metastasis chronically.
Scientists discover that 3' UTRs of mRNAs actively guide protein folding during translation, controlling activity of key cancer and aging regulators.
A new commentary in Gut raises important concerns about using large language models to detect colorectal polyps in endoscopic images.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
A first-in-human Phase 1/2 trial of ISB 1442 in relapsed/refractory multiple myeloma was halted before completion.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Cancer cells that downregulate SMC4 enter a low-proliferation, diapause-like state that resists standard chemotherapy, revealing a dangerous survival mechanism.
